NASDAQ:KLDO

Kaleido Biosciences Stock Forecast, Price & News

$9.84

+0.08 (+0.82 %)

(As of 02/24/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.59

Now: $9.84▼

$10.31

50-Day Range

$9.76

MA: $12.14▼

$16.82

52-Week Range

$2.82

Now: $9.84▼

$20.50

Volume170,381 shs

Average Volume326,344 shs

Market Capitalization$354.06 million

P/E RatioN/A

Dividend YieldN/A

Beta0.02

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Headlines

Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
February 24, 2021 | nasdaq.com

Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
February 12, 2021 | marketwatch.com

Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
February 11, 2021 | finance.yahoo.com

What Is The Ownership Structure Like For Kaleido Biosciences, Inc. (NASDAQ:KLDO)?
February 9, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
January 20, 2021 | finance.yahoo.com

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
January 14, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 | finance.yahoo.com

Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
January 4, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 | finance.yahoo.com

Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 2, 2020 | finance.yahoo.com

Flagship Pioneering Unveils Senda Biosciences to pioneer Intersystems Biology and create novel treatments for human disease
October 30, 2020 | prnewswire.com

Analysts Have Just Cut Their Kaleido Biosciences, Inc. (NASDAQ:KLDO) Revenue Estimates By 20%
October 23, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KLDO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.kaleido.com

Phone617 674 9000

Employees91

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares35,982,000

Market Cap$354.06 million

Next Earnings Date3/1/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.84 out of 5 stars

Medical Sector

117th out of 1,958 stocks

Biotechnology Industry

3rd out of 114 stocks

3.3 Analyst's Opinion

Consensus Rating
Kaleido Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.88, Kaleido Biosciences has a forecasted upside of 81.7% from its current price of $9.84.
Amount of Analyst Coverage
Kaleido Biosciences has only been the subject of 4 research reports in the past 90 days.

2.0 Community Rank

Outperform Votes
Kaleido Biosciences has received 43 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kaleido Biosciences has received 64 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kaleido Biosciences has received 59.81% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote “Outperform” if you believe KLDO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kaleido Biosciences does not currently pay a dividend.
Dividend Growth
Kaleido Biosciences does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kaleido Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,472,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.00% of the stock of Kaleido Biosciences is held by insiders.
Percentage Held by Institutions
79.91% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Kaleido Biosciences are expected to grow in the coming year, from ($2.31) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kaleido Biosciences is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kaleido Biosciences is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$9.84

+0.08 (+0.82 %)

(As of 02/24/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

Is Kaleido Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kaleido Biosciences stock.
View analyst ratings for Kaleido Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Kaleido Biosciences?

Wall Street analysts have given Kaleido Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaleido Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Kaleido Biosciences.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its quarterly earnings data on Saturday, November, 7th. The company reported ($0.65) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.03. The business earned $0.48 million during the quarter.
View Kaleido Biosciences' earnings history.

How has Kaleido Biosciences' stock price been impacted by Coronavirus?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KLDO stock has increased by 77.6% and is now trading at $9.84.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KLDO?

6 Wall Street analysts have issued 1-year price targets for Kaleido Biosciences' shares. Their forecasts range from $13.00 to $22.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.88 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price.
View analysts' price targets for Kaleido Biosciences or view top-rated stocks among Wall Street analysts.

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:

Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 40, Pay $35k)
Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 42, Pay $464.81k)
Dr. Katharine Knobil M.D., Consultant (Age 56, Pay $668.03k)
Mr. Daniel L. Menichella B.A., M.B.A., Pres, CEO & Director (Age 62)
Mr. William E. Duke Jr., Chief Financial Officer (Age 49)
Dr. Johan van Hylckama Vlieg, Chief Scientific Officer
Ms. Susan Stewart J.D., Chief Regulatory Affairs Officer (Age 59)
Ms. Clare Fisher, Chief Bus. Officer

Who are some of Kaleido Biosciences' key competitors?

Some companies that are related to Kaleido Biosciences include Nurix Therapeutics (NRIX), Concordia International Corp. (CXR.TO) (CXR), PureTech Health (PRTC), Pharvaris (PHVS), 4D Molecular Therapeutics (FDMT), Oxford Biomedica plc (OXB.L) (OXB), Angion Biomedica (ANGN), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Inventiva (IVA), 22nd Century Group (XXII), Landos Biopharma (LABP), NexImmune (NEXI), Terns Pharmaceuticals (TERN) and Burcon NutraScience Co. (BU.TO) (BU).
View all of KLDO's competitors.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include HarbourVest Partners LLC (5.10%), BlackRock Inc. (2.61%), Charles Schwab Investment Management Inc. (0.25%), Nuveen Asset Management LLC (0.18%), First Trust Advisors LP (0.11%) and Bank of New York Mellon Corp (0.11%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship and Ventures Fund V LP Flagship.
View institutional ownership trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including HarbourVest Partners LLC, Charles Schwab Investment Management Inc., Barclays PLC, and First Trust Advisors LP.
View insider buying and selling activity for Kaleido Biosciences or view top insider-selling stocks.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State of Wisconsin Investment Board, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., and Citigroup Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship, and Ventures Fund V LP Flagship.
View insider buying and selling activity for Kaleido Biosciences or or view top insider-buying stocks.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $9.84.

How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of $354.06 million.

How many employees does Kaleido Biosciences have?

Kaleido Biosciences employs 91 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is www.kaleido.com.

How can I contact Kaleido Biosciences?

The company can be reached via phone at 617 674 9000.

This page was last updated on 2/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here